Aspiriant LLC’s Xtrackers MSCI EAFE Hedged Equity ETF DBEF Stock Holding History

Aspiriant LLC’s Portfolio DBEF Stock Details DBEF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-71,505	Closed	-$2.05M	–	190
2016 Q2	$2.05M	Sell	71,505 -37,752	-35%	-$967K	0.19%	73
2016 Q1	$2.79M	Buy	+109,257	New	+$2.76M	0.27%	55

Other funds holding DBEF

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Aspiriant LLC's DBEF Position: Q3 2016 in Review

Aspiriant LLC sold out of Xtrackers MSCI EAFE Hedged Equity ETF (DBEF) in Q3 2016, closing a stake of 71,505 shares — an estimated $2.05M sold.

Aspiriant LLC first reported a position in DBEF in Q1 2016 and held it in 2 quarters. The position peaked at $2.79M in Q1 2016. 181 funds tracked by Wall St. Rank hold DBEF as of Q3 2016.

Aspiriant LLC reported no remaining Xtrackers MSCI EAFE Hedged Equity ETF position as of Q3 2016 after selling out during the quarter.
Aspiriant LLC sold 71,505 Xtrackers MSCI EAFE Hedged Equity ETF shares in Q3 2016, an estimated $2.05M.
Aspiriant LLC first reported a position in Xtrackers MSCI EAFE Hedged Equity ETF in Q1 2016 and held it in 2 quarters.
Aspiriant LLC's Xtrackers MSCI EAFE Hedged Equity ETF position peaked at $2.79M in Q1 2016.
181 funds tracked by Wall St. Rank held Xtrackers MSCI EAFE Hedged Equity ETF as of Q3 2016.

Based on Aspiriant LLC's 13F filing for Q3 2016, filed 10 Nov 2016.